U.S. Federal Trade Commission Lays Down the Law on Deceptive CBD Claims December 18, 2020 Contact Author Rachel Grabenhofer
Close
Sponsored
The U.S. Federal Trade Commission (FTC) announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. Oils, balms, gummies, coffee and other goods were among the product types cited.
The FTC reports it is taking action against six sellers of CBD-containing products for making a wide range of scientifically unsupported claims about the products abilities to treat serious health conditions including cancer, heart disease, hypertension, Alzheimer’s disease and others.
The agency is requiring each of the companies and individuals behind them to stop making these unsupported claims immediately, and several will pay monetary judgments. The orders settling the FTC’s complaints also bar the respondents from similar deceptive advertising in the future, and require them to
By City News Service
Dec 18, 2020
LOS ANGELES (CNS) - The Federal Trade Commission announced the first law enforcement crackdown on deceptive claims in the growing market for cannabidiol products this week, naming companies in Los Angeles, Riverside and Orange counties.
The FTC is taking action against the sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer s disease and others.
The FTC is requiring the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency. The orders settling the FTC s complaints also bar the respondents from similar deceptive advertising in the future, and
FTC enforcement action targets six CBD firms over unsubstantiated claims The Federal Trade Commission unveiled an enforcement action today against six sellers of CBD products that it alleges have been making unsubstantiated disease treatment claims. FTC has levied more than $246,000 in fines in the cases.
The action was announced on the agency’s website this morning. According to the statement, the CBD firms (two firms also market CBG products) were allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others.
The six companies will be required to stop making the claims immediately. Fines were levied in all but one of the cases. The fines ranged from $20,000 to $85,000. In addition to the fines the defendants are prohibited in the future from making health benefit claims without competent and reliable sc
Andrew Smith, Director, Bureau of Consumer Protection on Thursday, December 17, 2020.
The Federal Trade Commission today announced the first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The FTC is taking action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others.
The FTC is requiring each of the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency. The orders settling the FTC’s complaints also bar the respondents from similar deceptive advertising in the future, and require that they have scientific evidence to support any health claims they make for CBD and other products.
“It’s the Wild West out there!” How often have you heard that statement made about health claims for products containing CBD? But here’s the thing: It’s not the Wild West. In fact, health-related representations for CBD products are subject to the same established requirements of scientific substantiation the FTC has applied for decades to any advertised health claim. That’s the message of Operation CBDeceit, a law enforcement sweep challenging allegedly unproven representations that CBD products would treat diseases and serious medical conditions like cancer, diabetes, Alzheimer’s disease, and more.
In Operation CBDeceit, the FTC announced proposed settlements with six companies that marketed gummies, lozenges, oils, balms, and other products containing cannabidiol (CBD) to prevent or treat serious diseases and health conditions.